IMMUNOLOGY MARKET ANALYSIS

Immunology Market Size and Trends

Global immunology market is estimated to be valued at USD 96.51 Bn in 2024 and is expected to reach USD 216.10 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.2% from 2024 to 2031.

Discover market dynamics shaping the industry: Request sample copy

Global immunology market is expected to witness significant growth over the forecast period due to  factors such as high prevalence of autoimmune and immunology disorders, rising demand for monoclonal antibodies and immunotherapy, and strong pipeline of immunology drugs.  Increasing healthcare expenditures and availability of research funds for immunology research globally Can also drive the market growth.

Rising Prevalence of Autoimmune Diseases

Increasing prevalence of various autoimmune diseases across the globe can drive the immunology market growth. Autoimmune diseases occur when the body's immune system mistakenly attacks and destroys healthy body tissues. Some of the most common autoimmune disorders include rheumatoid arthritis, Type 1 diabetes, multiple sclerosis, inflammatory bowel disease, psoriasis, lupus and others. For instance, in February 2022, according to the data from Canadian Cancer Statistics Report, 233,900 persons were diagnosed with cancer  in 2022. The most common cancers, according to the research, are colon, prostate, and breast cancers. When combined, these represent about 50% of all common instances. Due to high incidence of cancer in nations like Canada, there has been increase in research activities to produce new medications.

Market Concentration and Competitive Landscape

Get actionable strategies to beat competition: Request sample copy

Rising Health Expenditure and Improving Access to Care

Rising health expenditure globally can drive the market growth. Rising disposable incomes, growing focus on healthcare, increasing medical insurance penetration and better access to healthcare facilities have enabled more patients to afford and qualify for expensive procedures such as immunology market. In developed nations, the overall rise in per capita healthcare spending supports ongoing technological advancements and innovations to improve success rates of organ transplantation. Developing markets, which account for the majority of the disease burden, are witnessing increased expenditures on complex transplant surgeries. This is primarily attributed to extensive primary market research over time by governments and private organizations to elevate standards of medical care and make healthcare affordable for greater population. Consequently, more patients worldwide now have access to various stages of immunology market including pre-transplant evaluation, immunosuppressive therapy post transplantation and long-term medical management, thus, boosting demand for related services, devices and drugs. In January 2023, according to the report published by American Cancer Society, there will be over 27.5 million new cancer cases and 16.3 million deaths by 2040 due to population growth and aging. Risk factors like smoking and poor diet are rising, especially in developing nations, and this increases disease burden. Pharmaceutical firms are intensifying R&D for innovative drugs amidst the surge in chronic diseases.

Key Takeaways from Analyst:

Global immunology market growth is driven by increasing prevalence of kidney failure and kidney diseases. Growing awareness about organ donation and transplantation can also drive the market growth. Moreover, technological advancements in transplantation procedures  is also fueling market expansion.

However, high costs associated with immunology surgeries and lifelong immunosuppressant drugs can hamper the market growth. The limited availability of organ donors can also pose challenge. Strict regulations regarding organ transplantation in some countries can hamper the market growth.

North America currently dominates the global immunology market and is expected to continue its leadership during the forecast period. This can be attributed to rising incidence of ESRD, favorable reimbursement policies, and presence of highly developed healthcare infrastructure in the region. The Asia Pacific market is likely to witness the fastest growth owing to increasing healthcare expenditure, growing medical tourism, and rising patient pool.

Market Challenges: High costs associated with immunology drugs and therapies.

High costs associated with immunology drugs and therapies can hamper the growth of the immunology market. Developing novel and innovative treatment options for various immunological disorders like cancer, arthritis, multiple sclerosis, and others requires massive investments in research and clinical trials. This entire process from drug discovery to final approvals is highly complex, risky and capital intensive. According to the data published by WHO in 2022, the average cost of developing a new drug and bringing it to the market is estimated to be around US$ 2.6 billion. This massive price increases the overall treatment costs significantly. For instance, on May 25, 2024, AstraZeneca suggests significant cost savings for health systems in four European countries through early CKD screening and treatment. This could prevent numerous heart attacks, heart failure hospitalizations, and strokes. Studies presented at the ERA Congress support the benefits of targeted screening and guideline-directed treatment, showing potential clinical benefits and cost savings.

Market Opportunities: Adoption of combination therapies

The adoption of combination therapies can offer growth opportunities for the market. Diseases are highly complex with multiple pathways contributing to pathogenesis. In 2021, according to a report published by World Health Organization, over 30% of cancer deaths can be linked to infectious diseases and chronic inflammation. Targeting the immune system through complementary mechanisms therefore holds promise. As research disentangles more immunological secrets, one may see tailored combination protocols that hit specific disease drivers emerging as the standards of care. This could both improve patient outcomes and sustain the growth of the immunology market well into the future by addressing currently unmet needs.

Discover high revenue pocket segments and roadmap to it: Request sample copy

By Drug Class:  Innovation and effectiveness drives monoclonal antibody segment growth

In terms of drug class, monoclonal antibody (mAb) segment is estimated to contribute the highest market share of 45.5% in 2024, owing  to continuous innovation and proven effectiveness in treating various immune disorders. Being a precise and potent biologic drug class, mAbs have revolutionized treatment landscapes for rheumatoid arthritis, cancer, and other diseases. Their ability to selectively target specific proteins and receptors with high specificity and low toxicity has made them superior to other drug modalities. Continued research and development over the past few decades have improved mAb design and production technologies. Advancements such as humanization, small modular immunopharmaceuticals, bispecific antibodies, and other modalities have enhanced mAb half-life, safety, and multi-targeting abilities. This has enabled development of more effective and convenient therapies. For example, subcutaneous long-acting mAbs have improved treatment adherence over intravenous infusions.

By Disease Indication:  High disease prevalence propels rheumatoid arthritis segment growth

In terms of disease indication, rheumatoid arthritis segment is estimated to contribute the highest market share of 25.2 % in 2024. It is one of the most common autoimmune diseases globally, affecting over 20 million patients worldwide. The chronic inflammation it causes can lead to long-term joint damage, disability and reduced quality of life if left untreated. Rheumatoid arthritis has a substantial socioeconomic burden worldwide. It typically affects people during their most productive years and can result in work disability. The need to effectively manage this prevalent condition boosts demand for disease-modifying anti-rheumatic drugs (DMARDs) and other targeted therapies. Biologic DMARDs such as anti-TNF mAbs have demonstrated superior efficacy and tolerability as compared to synthetic DMARDs in clinical practice.

By Distribution Channel: Convenient access and reimbursement favors hospital pharmacies segment growth

In terms of distribution channel, hospital pharmacies segment is estimated to contribute the highest market share of 40.12% in 2024. As administered biologics need specialized storage and handling, hospital settings offer ready access and convenience for infused therapies. Many health insurance plans also mandate initial infusions be done in hospitals for safety. This direct distribution method assures medication adherence by bringing treatment to the patient. Aside from stocking requirements, hospital pharmacies have trained staff, facilities and protocols to administer biologics under medical supervision. For self-injectables, nurses provide instruction to ensure proper dosage and storage. This decreases administration errors and adverse events. Hospital dispensing also permits monitoring of patient response and management of infusion reactions.

Regional Insights

To learn more about this report, Request sample copy

North America has established itself as the dominant region in the global immunology market with estimated market share of 40.2 % in 2024 due to strong presence of pharmaceutical companies and growing biotechnology industry in the region. The U.S.  accounts for the largest share and has presence of most number of companies involved in research, development and manufacturing of immunology drugs. The region also has well-established healthcare infrastructure and high healthcare spending that provides conducive environment for development and adoption of advanced treatment options.

Stringent regulations ensure that safe and effective drugs are brought to market. Presence of key opinion leaders and research centers drive clinical trials and innovations. Favorable reimbursement policies increase affordability and access to life-saving treatment options for patients. The region also exports immunology drugs to other markets, and thus, contributes significantly to the market growth. However, pricing pressures in U.S. may impact revenue growth of pharmaceutical companies in coming years.

Asia Pacific region has emerged as the fastest growing market. Rapid economic development, growing healthcare infrastructure and increasing accessibility in major countries like China and India is driving the market growth. Rising awareness about conditions treated through immunology and increasing disposable income can boost healthcare spending. Governments are also focusing on enhancing healthcare facilities and spurring medical innovations through initiatives like 'Make in India'.

Market Report Scope

Immunology Industry News

• On May 22, 2024, Biogen Inc, an American multinational biotechnology company, and Human Immunology Biosciences, a privately-held clinical-stage biotechnology firm specializing in tailored treatments for individuals with severe immune-mediated diseases (IMDs), announced that both companies had signed definitive agreement. According to the agreement, Biogen will purchase HI-Bio for an initial sum of US$ 1.15 billion, with the potential for additional milestone payments totaling up to US$ 650 million.
• On May 15, 2024, Blackstone, a investment management company, introduced Uniquity Bio, a clinical-stage drug development company concentrating on immunology and inflammation, within the Blackstone Life Sciences (“Blackstone”) portfolio. Uniquity Bio emerges from secrecy with the FDA's approval of its Phase 2 investigational new drug (“IND”) application for solrikitug, a monoclonal antibody aimed at TSLP, and is set to receive up to US$300 million in funding from Blackstone to progress the asset across various indications.
• In April 2023, Merck, recognized as MSD, a multinational science and technology company, and Prometheus Biosciences, Inc., a biopharmaceutical company, announced that both companies had signed a definitive agreement. According to this agreement, Merck, via a subsidiary, will purchase Prometheus for US$ 200.00 per share in cash.
• In November 2022, Genmab, a biotech company, and BioNTech, a Germany-based biotechnology company, collaborated to develop the DuoBody-PD-L1x4-1BB (GEN1046) monoclonal antibody for Phase 1/2 trials in solid tumors and Phase 2 trials in non-small cell lung cancer
• In October 2022, the U.S. FDA granted approval for the combination of durvalumab (Imfinzi) and tremelimumab (Imjudo) for individuals with unresectable hepatocellular carcinoma, the predominant form of liver cancer

*Definition: Immunology Market offers a wide range of products to support research and clinical testing in immunology. This particular product is an immunology assay kit designed for research use to detect and quantify various cytokines, chemokines, growth factors and other biomarkers important in immune response signaling pathways. The assay kit provides a sensitive and high-throughput method for profiling protein expression patterns involved in immune cell communication and related disease processes.

Market Segmentation

•  Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
  • Monoclonal Antibody (mAb)
  • Fusion Proteins
  • Immunosuppressants
  • Polyclonal Antibody (pAb)
  • Others
•  Disease Indication Insights (Revenue, USD Bn, 2019 - 2031)
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
  • Plaque Psoriasis
  • Ankylosing Spondylitis
  • Inflammatory Bowel Disease
  • Prophylaxis of Organ Rejection
  • Others
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • AbbVie Inc.
  • Johnson & Johnson
  • Amgen Inc.
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Novartis International AG
  • Bristol-Myers Squibb Company
  • Merck & Co., Inc.
  • AstraZeneca PLC
  • Sanofi
  • GlaxoSmithKline plc
  • UCB S.A.
  • Eli Lilly and Company
  • Gilead Sciences Inc.
  • Celgene Corporation
  • Biogen Inc.
  • Regeneron Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.